{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T02:59:42Z","timestamp":1792033182172,"version":"4.4.0"},"reference-count":7,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jdcr.2023.05.016","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T02:03:57Z","timestamp":1684721037000},"page":"89-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib"],"prefix":"10.1016","volume":"37","author":[{"given":"Lisa","family":"Van Eycken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Catherine","family":"Dens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"de Vlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Neerinckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"De Haes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jdcr.2023.05.016_bib1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"10.1016\/j.jdcr.2023.05.016_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.cgh.2018.10.047","article-title":"Tofacitinib for the treatment of pyoderma gangrenosum","volume":"17","author":"Kochar","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jdcr.2023.05.016_bib3","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jid.2021.08.431","article-title":"Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression","volume":"142","author":"Ortega-Loayza","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"10302","key":"10.1016\/j.jdcr.2023.05.016_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"Mclornan","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jdcr.2023.05.016_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s41927-018-0031-x","article-title":"In\u00a0vitro and in\u00a0vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"issue":"9","key":"10.1016\/j.jdcr.2023.05.016_bib7","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jdcr.2020.07.035","article-title":"Recalcitrant and severe pyoderma gangrenosum attributable to levamisole-adulterated cocaine and treated successfully with oral tofacitinib","volume":"6","author":"Choi","year":"2020","journal-title":"JAAD Case Rep"},{"issue":"4","key":"10.1016\/j.jdcr.2023.05.016_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/ddg.14716","article-title":"Response of rheumatoid arthritis-associated pyoderma gangrenous to the JAK1 inhibitor upadacitinib","volume":"20","author":"Kooybaran","year":"2022","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623001686?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512623001686?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:25:16Z","timestamp":1762475116000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512623001686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":7,"alternative-id":["S2352512623001686"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.016","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolution of therapy-resistant pyoderma gangrenosum with upadacitinib","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2023.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}